Home/Pipeline/ANORO ELLIPTA

ANORO ELLIPTA

COPD

CommercialRoyalty Revenue Generating

Key Facts

Indication

COPD

Phase

Commercial

Status

Royalty Revenue Generating

Company

Innoviva

About Innoviva

Innoviva operates a distinctive hybrid business model, leveraging long-term royalty streams from partnered respiratory drugs like TRELEGY and ANORO to fund strategic R&D and acquisitions. The company has successfully transitioned from its origins as Theravance into a financially robust entity with a $1.69B market cap, using its cash generation to build a promising pipeline in oncology and anti-infectives. Its strategy focuses on disciplined capital allocation, targeting late-stage or commercial assets to drive future growth while maintaining a strong balance sheet.

View full company profile

Therapeutic Areas

Respiratory Infectious Disease Oncology

Other COPD Drugs

Drug	Company	Phase	Status
Yupelri® (revefenacin)	Cleo Life Sciences	Approved	Supported early development CMC
Spiro Neuromodulation System	Spiro Medical	Phase 2	Active
VL-PX10 & VL-P22	Vitti Labs	Phase 2	Active
Solrikitug	Uniquity Bio	Phase 2	Active
CAL-4	Calyxha Biotechnologies	Discovery	Active
OligoG (Inhaled)	Algipharma	Phase 2	Active
Digital Biomarker for COPD	electronRx	Early Development	Active
Tozorakimab	AstraZeneca	Phase III	Active
Eclira Genuair (Acidinium Bromide)	KYORIN Pharmaceutical	Marketed	Active
GB-0895	Generate Biomedicines	Phase 1	Active